Pub Date : 2024-01-15DOI: 10.18231/j.ijpp.2023.046
P. Pavithra, S. Kavimani, P. Pavazhaviji, A. Hemalatha, R. Snega
a native traditional plant commonly known as Indian Mallow, is a versatile plant species that brings enormous amounts of medicinal uses from the history of traditional culture. This review emphasizes the current body of knowledge surrounding the effects of , highlighting its potential therapeutic application. The plant is well renowned for its diverse phytochemical composition, including alkaloids, flavonoids, and polysaccharides, which contribute to its wide-ranging biological activity. It has been discovered through research that Abutilon indicum extracts possess noteworthy pharmacological effects, including anti-oxidant, anti-inflammatory, anti-microbial, anti-diabetic, and hepatoprotective properties. In addition to its immunomodulatory effects, larvicidal, anti-convulsant, neuroprotective, and cognitive-enhancing capacities have gained attention in recent years and serve as natural alternatives to available allopathic medicine.The focus of the review revolves around various noteworthy pharmacological effects of , including its anti-inflammatory, anti-microbial, anti-oxidant, and anti-convulsant properties. Furthermore, the examination of the plant extracts' phytochemical composition is also emphasized.Those activities were discussed and reported with standard methods and compared with the available standard drugs. Overall, this comprehensive review provides valuable insights into the pharmacological effects of , underscoring its potential as a source of novel therapeutic agents and paving the way for future research and development.
{"title":"A review on phytochemical screening and pharmacological activities of fruit of Indian mallow","authors":"P. Pavithra, S. Kavimani, P. Pavazhaviji, A. Hemalatha, R. Snega","doi":"10.18231/j.ijpp.2023.046","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.046","url":null,"abstract":"a native traditional plant commonly known as Indian Mallow, is a versatile plant species that brings enormous amounts of medicinal uses from the history of traditional culture. This review emphasizes the current body of knowledge surrounding the effects of , highlighting its potential therapeutic application. The plant is well renowned for its diverse phytochemical composition, including alkaloids, flavonoids, and polysaccharides, which contribute to its wide-ranging biological activity. It has been discovered through research that Abutilon indicum extracts possess noteworthy pharmacological effects, including anti-oxidant, anti-inflammatory, anti-microbial, anti-diabetic, and hepatoprotective properties. In addition to its immunomodulatory effects, larvicidal, anti-convulsant, neuroprotective, and cognitive-enhancing capacities have gained attention in recent years and serve as natural alternatives to available allopathic medicine.The focus of the review revolves around various noteworthy pharmacological effects of , including its anti-inflammatory, anti-microbial, anti-oxidant, and anti-convulsant properties. Furthermore, the examination of the plant extracts' phytochemical composition is also emphasized.Those activities were discussed and reported with standard methods and compared with the available standard drugs. Overall, this comprehensive review provides valuable insights into the pharmacological effects of , underscoring its potential as a source of novel therapeutic agents and paving the way for future research and development.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.18231/j.ijpp.2023.049
Akshay Hasmukhbhai Parmar, A. Sukhlecha, K. Katariya
Pharmacology, being both the basic and applied science of drugs, forms the backbone of rational therapeutics. With an emphasis on learning the facts of medications, traditional pharmacology teaching is mostly teacher-centred. The erroneous prescribing that can result from inadequate understanding can cost a great deal of money and lives. The aim of the present study was to assess doctors' prescription knowledge, attitudes, and practices.The information was gathered from postgraduate students (residents) using questionnaires about their undergraduate training in clinical pharmacology and therapeutics, prescribing practices, frequently used drug information sources, and any perceived shortcomings in their undergraduate clinical pharmacology teaching. There was a calculation of descriptive statistics and a chi-square test.Among the 149 responses, 86 (57.71%) of them were male and 63 (42.28%) were female. Only 33 (22.1%) participants knew the components of a prescription, and 135 (90.6%) participants were aware that prescription writing was taught in their undergraduate course. Around 41 (27.5%) participants were aware of the concept of P drugs. Among them, 89 (59.73%) residents had good knowledge of prescriptions. Only 35 (23.5%) strongly agreed, and 113 (75.8%) agreed that undergraduate pharmacology training taught them to prescribe safely. About 83 (55.7%) participants disagreed, 33 (22.1%) strongly disagreed, and only 10 (6.7%) agreed that undergraduate pharmacology teaching should be improved. According to the patient's needs, 146 (98%) participants were prescribed additional vitamins and irons. Around 52 (34.9%) participants reported having difficulty prescribing during their internship rotation. Among them, 77 (51.67%) residents had good practice of prescription.A majority of postgraduate students believed that additional training should be provided on writing rational prescriptions to make them more confident in their prescribing practices.
{"title":"Knowledge, attitude and practices related to drug prescription among postgraduate medical students: A cross sectional study","authors":"Akshay Hasmukhbhai Parmar, A. Sukhlecha, K. Katariya","doi":"10.18231/j.ijpp.2023.049","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.049","url":null,"abstract":"Pharmacology, being both the basic and applied science of drugs, forms the backbone of rational therapeutics. With an emphasis on learning the facts of medications, traditional pharmacology teaching is mostly teacher-centred. The erroneous prescribing that can result from inadequate understanding can cost a great deal of money and lives. The aim of the present study was to assess doctors' prescription knowledge, attitudes, and practices.The information was gathered from postgraduate students (residents) using questionnaires about their undergraduate training in clinical pharmacology and therapeutics, prescribing practices, frequently used drug information sources, and any perceived shortcomings in their undergraduate clinical pharmacology teaching. There was a calculation of descriptive statistics and a chi-square test.Among the 149 responses, 86 (57.71%) of them were male and 63 (42.28%) were female. Only 33 (22.1%) participants knew the components of a prescription, and 135 (90.6%) participants were aware that prescription writing was taught in their undergraduate course. Around 41 (27.5%) participants were aware of the concept of P drugs. Among them, 89 (59.73%) residents had good knowledge of prescriptions. Only 35 (23.5%) strongly agreed, and 113 (75.8%) agreed that undergraduate pharmacology training taught them to prescribe safely. About 83 (55.7%) participants disagreed, 33 (22.1%) strongly disagreed, and only 10 (6.7%) agreed that undergraduate pharmacology teaching should be improved. According to the patient's needs, 146 (98%) participants were prescribed additional vitamins and irons. Around 52 (34.9%) participants reported having difficulty prescribing during their internship rotation. Among them, 77 (51.67%) residents had good practice of prescription.A majority of postgraduate students believed that additional training should be provided on writing rational prescriptions to make them more confident in their prescribing practices.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.18231/j.ijpp.2023.053
K. K. Kurup, KP Shamabanu, NK Khadeejathul Nifana Nasrin, MM Hafshath, Muhammed Sinan Abdul Karim
Tuberculosis ranks among the top 10 causes of death globally and stands as the primary cause attributed to a single infectious agent. Among all antitubercular drugs, Isoniazid is most important role in the management of pulmonary tuberculosis.Various neuropsychiatric adverse effects have been documented in association with the use of isoniazid, both in therapeutic and overdose scenarios. This case report describes a 68-year-old male with multiple health issues, including disseminated tuberculosis, developed drug-induced psychosis, likely due to isoniazid in his anti-tubercular therapy. This case underscores the challenges of psychiatric adverse effects in tuberculosis treatment and emphasizes the importance of prompt recognition and intervention.
{"title":"ADR assessment of isoniazid induced psychosis: Case report and review of literature","authors":"K. K. Kurup, KP Shamabanu, NK Khadeejathul Nifana Nasrin, MM Hafshath, Muhammed Sinan Abdul Karim","doi":"10.18231/j.ijpp.2023.053","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.053","url":null,"abstract":"Tuberculosis ranks among the top 10 causes of death globally and stands as the primary cause attributed to a single infectious agent. Among all antitubercular drugs, Isoniazid is most important role in the management of pulmonary tuberculosis.Various neuropsychiatric adverse effects have been documented in association with the use of isoniazid, both in therapeutic and overdose scenarios. This case report describes a 68-year-old male with multiple health issues, including disseminated tuberculosis, developed drug-induced psychosis, likely due to isoniazid in his anti-tubercular therapy. This case underscores the challenges of psychiatric adverse effects in tuberculosis treatment and emphasizes the importance of prompt recognition and intervention.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":" 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Skin and soft tissue infections (SSTIs) are common and can have serious implications.Nadifloxacin’s broad-spectrum antibiotic activity may potentially provide therapeutic benefits for skininfections. Also, it offers a viable alternative therapy for topical agent resistance. This study investigates the antimicrobial susceptibility of eight micro-organisms to four important topical antibiotics: Mupirocin, Clindamycin, Fusidic acid, and Nadifloxacin. Antibiotic susceptibility and minimum inhibitory concentration (MIC) were determined using Kirby-Bauer disk diffusion, Epsilometer test (E-Test), and Micro-broth dilution methods. Mueller Hinton and Brucella blood agar served as growth media. HiComb strips from HiMedia were used, and QC strains were tested. Kirby-Bauer assessed Zone of Inhibition; HiComb determined MIC via gradient; Micro-broth dilution gauged growth in antibiotic-diluted broth. The disk diffusion method revealed varying resistance percentages for antibiotics. Clindamycin had the highest resistance (62%) followed by fusidic acid (47%), Nadifloxacin (15%), and mupirocin (5%). Among gram-positive isolates, Nadifloxacin and mupirocin had 100% sensitivity, while Fusidic acid showed moderate resistance (19%) and clindamycin highest resistance (42%). Among gram-negative isolates, clindamycin and fusidic acid had 100% resistance, while Nadifloxacin (42%) and mupirocin (15%) showed comparatively low resistance. Among the 57 species isolates, including 49 isolates of and 8 isolates of the antibiotic susceptibility testing revealed a MIC value <4 μg/ml of Nadifloxacin, with a high level of sensitivity across all isolates. Nadifloxacin’s superior efficacy in the study can be attributed to its mechanism of action, targeting bacterial DNA gyrase and topoisomerase IV, making it suitable for bacterial infections, particularly those involving the skin and soft tissuesOut of four antibiotics tested, Nadifloxacin was found to be effective against both gram-positive and gram-negative strains of bacteria.
{"title":"Antibiotic resistance and susceptibility pattern of different microorganisms against nadifloxacin","authors":"Monil Yogesh Neena Gala, Snehal Muchhala, Seema Bhagat, Arti Sanghavi, Rahul Rathod, Bhavesh Kotak, Rashmi Khadapkar","doi":"10.18231/j.ijpp.2023.039","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.039","url":null,"abstract":"Skin and soft tissue infections (SSTIs) are common and can have serious implications.Nadifloxacin’s broad-spectrum antibiotic activity may potentially provide therapeutic benefits for skininfections. Also, it offers a viable alternative therapy for topical agent resistance. This study investigates the antimicrobial susceptibility of eight micro-organisms to four important topical antibiotics: Mupirocin, Clindamycin, Fusidic acid, and Nadifloxacin. Antibiotic susceptibility and minimum inhibitory concentration (MIC) were determined using Kirby-Bauer disk diffusion, Epsilometer test (E-Test), and Micro-broth dilution methods. Mueller Hinton and Brucella blood agar served as growth media. HiComb strips from HiMedia were used, and QC strains were tested. Kirby-Bauer assessed Zone of Inhibition; HiComb determined MIC via gradient; Micro-broth dilution gauged growth in antibiotic-diluted broth. The disk diffusion method revealed varying resistance percentages for antibiotics. Clindamycin had the highest resistance (62%) followed by fusidic acid (47%), Nadifloxacin (15%), and mupirocin (5%). Among gram-positive isolates, Nadifloxacin and mupirocin had 100% sensitivity, while Fusidic acid showed moderate resistance (19%) and clindamycin highest resistance (42%). Among gram-negative isolates, clindamycin and fusidic acid had 100% resistance, while Nadifloxacin (42%) and mupirocin (15%) showed comparatively low resistance. Among the 57 species isolates, including 49 isolates of and 8 isolates of the antibiotic susceptibility testing revealed a MIC value &#60;4 μg/ml of Nadifloxacin, with a high level of sensitivity across all isolates. Nadifloxacin’s superior efficacy in the study can be attributed to its mechanism of action, targeting bacterial DNA gyrase and topoisomerase IV, making it suitable for bacterial infections, particularly those involving the skin and soft tissuesOut of four antibiotics tested, Nadifloxacin was found to be effective against both gram-positive and gram-negative strains of bacteria.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"107 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135758780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-15DOI: 10.18231/j.ijpp.2023.028
John Praveen, Thirumalai Velu Swaminathan
The article offers an extensive evaluation of cosmetovigilance and its pivotal contribution to ensuring the safety and integrity of cosmetic products. It delves into the multifaceted cosmetics industry, encompassing segments like cosmeceuticals, nutricosmetics, and cosmetic devices, each tailored to enhance personal care. In addition to unveiling the details of cosmetovigilance, this article sheds light on a pressing concern – counterfeit beauty products. It underscores the hazards lurking within these deceptive imitations, emphasizing the necessity of consumer awareness and vigilance. The article equips readers with practical strategies to navigate the intricate landscape of cosmetics, evade harmful chemicals, and protect their well-being. Above all, this article underscores the profound significance of cosmetovigilance as the sentinel of product safety and consumer welfare. It offers insights into the latest industry trends, regulatory adaptations, and the responsibilities entailed in reporting adverse events. Serving as an enduring reminder, it reinforces the enduring necessity for unwavering vigilance in the realm of cosmetics.
{"title":"Cosmetovigilance: Emerging safety trends","authors":"John Praveen, Thirumalai Velu Swaminathan","doi":"10.18231/j.ijpp.2023.028","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.028","url":null,"abstract":"The article offers an extensive evaluation of cosmetovigilance and its pivotal contribution to ensuring the safety and integrity of cosmetic products. It delves into the multifaceted cosmetics industry, encompassing segments like cosmeceuticals, nutricosmetics, and cosmetic devices, each tailored to enhance personal care. In addition to unveiling the details of cosmetovigilance, this article sheds light on a pressing concern – counterfeit beauty products. It underscores the hazards lurking within these deceptive imitations, emphasizing the necessity of consumer awareness and vigilance. The article equips readers with practical strategies to navigate the intricate landscape of cosmetics, evade harmful chemicals, and protect their well-being. Above all, this article underscores the profound significance of cosmetovigilance as the sentinel of product safety and consumer welfare. It offers insights into the latest industry trends, regulatory adaptations, and the responsibilities entailed in reporting adverse events. Serving as an enduring reminder, it reinforces the enduring necessity for unwavering vigilance in the realm of cosmetics.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"143 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study was carried out to assess the in vitro dissolution of Butaproxyvon Capsule (Paracetamol 325mg and Diclofenac 50mg) by calculating the percentage mean drug dissolved and disintegration time, as well as acid neutralizing time. The capsules were tested using three different types of dissolution medium, including pH6.8 phosphate buffer, pH7.5 phosphate buffer, and pH4.5 acetate buffer. The disintegration apparatus was used to calculate the disintegration time, and the acid neutralizing capacity was determined by titrating the capsule content mix with hydrochloric acid with 0.5N sodium hydroxide. Acid neutralizing capacity was found 12.33 mEq/g. Disintegration time was found in the range of 4.40 to 10.00 minutes. % Mean Paracetamol release was found to be almost similar after 60 minutes in all media. % Mean Diclofenac Potassium release was to be found almost similar after 60 minutes by using pH 6.8 and pH 7.5 phosphate media. % Mean drug released for Diclofenac Potassium was found 13% in 4.5 Acetate media, and the released pattern was not uniform. This may be attributed to the low solubility of Diclofenac potassium in 4.5 Acetate media.
{"title":"Assessment of dissolution, disintegration time, and acid-neutralizing capacity of Butaproxyvon capsules (Paracetamol 325mg and diclofenac potassium 50mg)","authors":"Mayank Dhore, Snehal Muchhala, Dhananjay Panigrahi, Seema Bhagat, Rahul Rathod, Bhavesh Kotak","doi":"10.18231/j.ijpp.2023.034","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.034","url":null,"abstract":"This study was carried out to assess the in vitro dissolution of Butaproxyvon Capsule (Paracetamol 325mg and Diclofenac 50mg) by calculating the percentage mean drug dissolved and disintegration time, as well as acid neutralizing time. The capsules were tested using three different types of dissolution medium, including pH6.8 phosphate buffer, pH7.5 phosphate buffer, and pH4.5 acetate buffer. The disintegration apparatus was used to calculate the disintegration time, and the acid neutralizing capacity was determined by titrating the capsule content mix with hydrochloric acid with 0.5N sodium hydroxide. Acid neutralizing capacity was found 12.33 mEq/g. Disintegration time was found in the range of 4.40 to 10.00 minutes. % Mean Paracetamol release was found to be almost similar after 60 minutes in all media. % Mean Diclofenac Potassium release was to be found almost similar after 60 minutes by using pH 6.8 and pH 7.5 phosphate media. % Mean drug released for Diclofenac Potassium was found 13% in 4.5 Acetate media, and the released pattern was not uniform. This may be attributed to the low solubility of Diclofenac potassium in 4.5 Acetate media.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-15DOI: 10.18231/j.ijpp.2023.030
Sunil Chaudhry, Abhijit Trailokya
PCSK 9 inhibitors currently have a market of 3 billion USD and by next 10 years it will raise to 13 billion USD in developed world. The rising prevalence of dyslipidemia and other lipid disorders are linked to lipid metabolism due to an unbalanced lifestyle and rising alcohol and tobacco use. PCSK9 inhibitors are injectable monoclonal antibodies that inactivate PCSK9 receptors. PCSK9 inhibition decreases degradation of the LDL receptor, thus raising the number of functioning LDL receptors on hepatocytes and lowering the number of LDL particles in the blood, which are atherogenic. For patients with very high cardiovascular risk, PCSK9 inhibitors and ezetimibe are added to statins, where they significantly lower absolute risk for myocardial infarction (MI) and stroke. Statins are known to upregulate PCSK9 encoding gene. PCSK9 inhibitors are given bimonthly or monthly and are reasonably safe. Familial Hypercholesterolemia (FH) a common inherited disorder of lipid metabolism, has mutations in one of these 3 genes: LDLR, APOB or PCSK9. These patients have 22 times more risk of coronary event than general population. Addition of a PCSK9 inhibitor to low dose statin therapy will be more effective in lowering LDL and avoiding the side effects of statins. PCSK9 inhibitors can contribute to both the stabilization and regression of atherosclerotic plaques and thereby avoid or delay major adverse cardiac events.
{"title":"Positioning of PCSK9 Inhibitors in hypercholesterolemia","authors":"Sunil Chaudhry, Abhijit Trailokya","doi":"10.18231/j.ijpp.2023.030","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.030","url":null,"abstract":"PCSK 9 inhibitors currently have a market of 3 billion USD and by next 10 years it will raise to 13 billion USD in developed world. The rising prevalence of dyslipidemia and other lipid disorders are linked to lipid metabolism due to an unbalanced lifestyle and rising alcohol and tobacco use. PCSK9 inhibitors are injectable monoclonal antibodies that inactivate PCSK9 receptors. PCSK9 inhibition decreases degradation of the LDL receptor, thus raising the number of functioning LDL receptors on hepatocytes and lowering the number of LDL particles in the blood, which are atherogenic. For patients with very high cardiovascular risk, PCSK9 inhibitors and ezetimibe are added to statins, where they significantly lower absolute risk for myocardial infarction (MI) and stroke. Statins are known to upregulate PCSK9 encoding gene. PCSK9 inhibitors are given bimonthly or monthly and are reasonably safe. Familial Hypercholesterolemia (FH) a common inherited disorder of lipid metabolism, has mutations in one of these 3 genes: LDLR, APOB or PCSK9. These patients have 22 times more risk of coronary event than general population. Addition of a PCSK9 inhibitor to low dose statin therapy will be more effective in lowering LDL and avoiding the side effects of statins. PCSK9 inhibitors can contribute to both the stabilization and regression of atherosclerotic plaques and thereby avoid or delay major adverse cardiac events.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-15DOI: 10.18231/j.ijpp.2023.031
Saba Wahid Khan, Alina Bi Shaikh, Mahnaz Sayyed, Muskan Shaikh
Effective medication delivery at a specific location has made it possible to carry out the intended task of controlling release rates and have better compliance with the healthcare system, but the chemistry's complex form has complicated things. However, the development of nanosponges has provided a key solution to this issue. Nanosponges are extremely tiny sponges that are roughly the size of a virus and can contain a range of medications. These sponges can move throughout the body until they interact with a particular target spot, attach to the surface, and begin to release drugs under regulated circumstances. Some cyclodextrin-based nanosponges have been proposed as nano-delivery systems, and they produce porous, insoluble nanoparticles with crystalline and amorphous natures. The solubility of these sponges in liquids is a crucial property.
{"title":"Novel trend: Magic bullet to nanomedicine as targeted drug delivery-nanosponges","authors":"Saba Wahid Khan, Alina Bi Shaikh, Mahnaz Sayyed, Muskan Shaikh","doi":"10.18231/j.ijpp.2023.031","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.031","url":null,"abstract":"Effective medication delivery at a specific location has made it possible to carry out the intended task of controlling release rates and have better compliance with the healthcare system, but the chemistry's complex form has complicated things. However, the development of nanosponges has provided a key solution to this issue. Nanosponges are extremely tiny sponges that are roughly the size of a virus and can contain a range of medications. These sponges can move throughout the body until they interact with a particular target spot, attach to the surface, and begin to release drugs under regulated circumstances. Some cyclodextrin-based nanosponges have been proposed as nano-delivery systems, and they produce porous, insoluble nanoparticles with crystalline and amorphous natures. The solubility of these sponges in liquids is a crucial property.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Quality is one of the most important issues in the pharmaceutical industry. Drugs must be marketed as safe and therapeutically effective formulations whose performance is consistent and foreseeable. evaluation verifies and ensures their quality, bioavailability, and optimum therapeutic activity. Aceclofenac and Paracetamol (acetaminophen) are commonly used for the relief of headaches and pain. The combination of these two drugs is available in different brands in the Indian market. The main objective of the present study was to conduct a comparative dissolution release test and acid neutralizing capacity test (ANC) of Test products versus Reference products. Brands that are similar in both composition and concentration were used in the study to compare the in vitro dissolution profile and ANC in different pH buffer solutions. Three marketed brands of Aceclofenac 100 mg and Paracetamol 325 mg, i.e., Aceproxyvon (test product Brand A), Brand B, and Brand C (Reference products), were used in the study. Brand D being an antacid was used as a reference product to compare the acid-neutralizing capacity of the drugs. The dissolution rates of paracetamol were similar across all formulations at various pH mediums. Aceclofenac showed a higher dissolution rate in Brand A as compared to Brand B and C at pH 4.5, while the dissolution rates of aceclofenac were comparable in all formulations using pH 6.8 and pH 7.5 phosphate media. The ANC of Brand A was found to be higher (7.42 mEq/g) compared to Brand B (6.74 mEq/g) and Brand C (7.18 mEq/g). Brand A showed faster dissolution and higher acid neutralizing capacity as compared to reference products. This enhancement in dissolution rate may further result in a rapid onset of action and better therapeutic efficacy.
{"title":"A comparative study of the dissolution rate and Acid-Neutralizing capacity of Aceproxyvon with other marketed drugs","authors":"Kanharam Narayanlal Patel, Seema Vikas Bhagat, Dhananjay Panigrahi, Snehal Sameer Muchhala, Rahul Tarachand Rathod, Bhavesh Prabhudas Kotak","doi":"10.18231/j.ijpp.2023.035","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.035","url":null,"abstract":"Quality is one of the most important issues in the pharmaceutical industry. Drugs must be marketed as safe and therapeutically effective formulations whose performance is consistent and foreseeable. evaluation verifies and ensures their quality, bioavailability, and optimum therapeutic activity. Aceclofenac and Paracetamol (acetaminophen) are commonly used for the relief of headaches and pain. The combination of these two drugs is available in different brands in the Indian market. The main objective of the present study was to conduct a comparative dissolution release test and acid neutralizing capacity test (ANC) of Test products versus Reference products. Brands that are similar in both composition and concentration were used in the study to compare the in vitro dissolution profile and ANC in different pH buffer solutions. Three marketed brands of Aceclofenac 100 mg and Paracetamol 325 mg, i.e., Aceproxyvon (test product Brand A), Brand B, and Brand C (Reference products), were used in the study. Brand D being an antacid was used as a reference product to compare the acid-neutralizing capacity of the drugs. The dissolution rates of paracetamol were similar across all formulations at various pH mediums. Aceclofenac showed a higher dissolution rate in Brand A as compared to Brand B and C at pH 4.5, while the dissolution rates of aceclofenac were comparable in all formulations using pH 6.8 and pH 7.5 phosphate media. The ANC of Brand A was found to be higher (7.42 mEq/g) compared to Brand B (6.74 mEq/g) and Brand C (7.18 mEq/g). Brand A showed faster dissolution and higher acid neutralizing capacity as compared to reference products. This enhancement in dissolution rate may further result in a rapid onset of action and better therapeutic efficacy.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135758773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-15DOI: 10.18231/j.ijpp.2023.040
Joshua George, Pavana Reddy, Stefy Jacob, M Sunitha, Vineeth Chandy
The objective of this study is to examine the existing evidence concerning the utilization of statins in individuals diagnosed with chronic liver disease and cirrhosis. Chronic liver diseases, such as cirrhosis and hepatocellular carcinoma, present substantial challenges to public health worldwide. The use of statins in these conditions has been a subject of concern due to potential liver injury risks. However, recent evidence from pre-clinical and clinical studies suggests that statins may have positive effects on disease progression, portal hypertension, and hepatocellular carcinoma prevention. These cholesterol-lowering drugs exhibit pleiotropic effects, including anti-inflammatory, anti-fibrotic, and antiangiogenic properties, which contribute to their potential benefits in chronic liver disease. While further research and randomized controlled trials are needed, statins offer a promising therapeutic avenue to prevent disease progression and improve outcomes in patients with chronic liver diseases. Despite the global burden of chronic liver diseases and the limited availability of effective medications, statins have emerged as potential agents to address these conditions. Their primary cholesterol-lowering effect is complemented by additional mechanisms that positively impact inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Although concerns persist regarding their hepatotoxic risks, studies have demonstrated the potential of statins to reduce the risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and mortality. Nonetheless, further large-scale randomized controlled trials focusing on clinical endpoints are necessary to ascertain the efficacy and safety of statin treatment in chronic liver diseases. Overall, statins hold promise as a valuable addition to the treatment armamentarium for chronic liver diseases, warranting further investigation and consideration in clinical practice.
{"title":"Current views and prospects relating to the use of statins in patients with chronic liver disease and cirrhosis","authors":"Joshua George, Pavana Reddy, Stefy Jacob, M Sunitha, Vineeth Chandy","doi":"10.18231/j.ijpp.2023.040","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.040","url":null,"abstract":"The objective of this study is to examine the existing evidence concerning the utilization of statins in individuals diagnosed with chronic liver disease and cirrhosis. Chronic liver diseases, such as cirrhosis and hepatocellular carcinoma, present substantial challenges to public health worldwide. The use of statins in these conditions has been a subject of concern due to potential liver injury risks. However, recent evidence from pre-clinical and clinical studies suggests that statins may have positive effects on disease progression, portal hypertension, and hepatocellular carcinoma prevention. These cholesterol-lowering drugs exhibit pleiotropic effects, including anti-inflammatory, anti-fibrotic, and antiangiogenic properties, which contribute to their potential benefits in chronic liver disease. While further research and randomized controlled trials are needed, statins offer a promising therapeutic avenue to prevent disease progression and improve outcomes in patients with chronic liver diseases. Despite the global burden of chronic liver diseases and the limited availability of effective medications, statins have emerged as potential agents to address these conditions. Their primary cholesterol-lowering effect is complemented by additional mechanisms that positively impact inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Although concerns persist regarding their hepatotoxic risks, studies have demonstrated the potential of statins to reduce the risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and mortality. Nonetheless, further large-scale randomized controlled trials focusing on clinical endpoints are necessary to ascertain the efficacy and safety of statin treatment in chronic liver diseases. Overall, statins hold promise as a valuable addition to the treatment armamentarium for chronic liver diseases, warranting further investigation and consideration in clinical practice.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135758644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：